Palisade Bio, Inc.
PALIHealthcare|Biotechnology|US
$1.13
-0.03 (-2.59%)
DCF Value
$2.39
Tangible Book / Share
$0.58
Cash / Share
$0.59
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07845487 A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis (UC), Severe Ulcerative Colitis | P2 | Recruiting | 204 | RCT, Double-blind | PALI-2108, PALI-2108, Placebo |
| NCT07428096 A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease | Fibrostenotic Crohn's Disease | P1 | Active | 6 | Open-label | PALI-2108 |
| NCT05470387 A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection | Ileus, Gastro-Intestinal Disorder | P3 | Terminated | 23 | RCT, Double-blind | LB1148, Placebo |
| NCT02317549 Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148 | Septic Shock | P2 | Terminated | 8 | RCT, Double-blind | LB1148, Placebo |
| NCT04390217 LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia | COVID-19, Coronavirus Disease 2019 | P2 | Withdrawn | — | RCT, Double-blind | LB1148, Placebo |
| NCT02836470 A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection | Ileus, Post-Operative Adhesions | P2 | Completed | 112 | RCT, Double-blind | LB1148, Placebo |
| NCT06663605 Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients. | Ulcerative Colitis (UC), Healthy Volunteer | P1 | Completed | 89 | RCT, Double-blind | PALI-2108, PALI-2108 Placebo |